Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 0

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 0
---
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-11960 AstraZeneca PLC 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA England Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

|             | ​ |             |
| Form 20-F ☒ | ​ | Form 40-F ☐ |

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

|       | ​ |      |
| Yes ☐ | ​ | No ☒ |

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-

29 July 2025 AstraZeneca results: H1 and Q2 2025 Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date Revenue and EPS summary

| ​                     | ​ | ​       |      ​ | ​ |        ​ | ​ |    ​ | ​ | ​ | ​       |      ​ | ​ |        ​ | ​ |   ​ |
| ​                     | ​ | H1 2025 |        | ​ | % Change |   |      | ​ | ​ | Q2 2025 |        | ​ | % Change |   |     |
| ​                     |   | $m      |        |   |   Actual |   | CER1 |   |   | $m      |        |   |   Actual |   | CER |
| - Product Sales       |   | ​       | 26,670 |   |        8 |   |   10 | ​ |   | ​       |